BHRT Statistics

47 million

women in the United States are currently in perimenopause or menopause, representing approximately 14% of the total US population.

75–85%

of menopausal women experience vasomotor symptoms (hot flashes and night sweats). Approximately 25–30% describe these symptoms as severe enough to significantly impair daily functioning and sleep.

~11%

of menopausal women currently use any form of hormone therapy in the United States — a rate that has not fully recovered from the post-WHI decline despite revised evidence and updated guidelines.

68%

decline in HRT prescriptions occurred between 2002 and 2004 following publication of the initial WHI study results, representing one of the most abrupt treatment reversals in modern medicine.

1–2%

annual decline in testosterone levels in men after age 30, compounding to a 30–40% reduction by age 70. An estimated 2–4 million American men have clinically low testosterone, with far more experiencing suboptimal levels without formal diagnosis.

8–10 years

is the typical duration of perimenopause — the transitional phase before menopause. Hormone fluctuations and symptoms can begin a full decade before the final menstrual period, often in a woman's mid-to-late 40s.

51 years

is the average age of natural menopause in the United States. The range for natural menopause is broadly 45–55; onset before 40 is classified as premature ovarian insufficiency (POI).

$300–$700

is the typical cost per pellet therapy insertion cycle, covering 3–6 months of hormone delivery. Annual costs for pellet therapy range from approximately $600–$1,400 depending on provider, location, and hormone combination.

$150–$350

is the typical range for an initial BHRT consultation, which includes a clinical assessment and baseline hormone panel review. Laboratory costs for a comprehensive hormone panel typically add $200–$500 unless covered by insurance.

Generally not covered

Compounded BHRT is not covered by most insurance plans. FDA-approved bioidentical hormones (estradiol patches, gels, and micronized progesterone) are frequently covered when prescribed for an approved indication — check your plan's formulary for specific coverage.

$5.4 billion

was the estimated global value of the hormone replacement therapy market in 2022, projected to reach $8.8 billion by 2030, driven by aging demographics and growing awareness of HRT's health benefits beyond symptom management.

3,000+

compounding pharmacies in the United States are estimated to specialize in hormone preparations. Quality varies considerably; PCAB accreditation is the clearest independent quality signal for patients evaluating a pharmacy.

30–35%

reduction in hip fracture risk associated with hormone therapy use, making HRT one of the most effective interventions for osteoporosis prevention. Effect size is comparable to bisphosphonate medications and sustained only during active use.

32%

reduction in cardiovascular events observed in women who initiated hormone therapy within 10 years of menopause onset, compared to women who did not use hormone therapy. The timing hypothesis: earlier initiation confers benefit; late initiation does not.

75–80%

reduction in hot flash frequency and severity is typical with hormone therapy in appropriately treated patients, making it significantly more effective than all non-hormonal alternatives including SSRIs, SNRIs, and gabapentin.

85%+

patient satisfaction rate is reported in observational studies of subcutaneous pellet therapy, with patients citing consistency of symptom relief, reduced dosing frequency, and improved quality of life compared to topical formulations.

Emerging evidence

suggests that early hormone therapy initiation may reduce Alzheimer's disease risk by 26–48% in women. The evidence is observational and the effect is timing-dependent — late initiation does not confer the same protection and may increase risk.

50%

of women who discontinue hormone therapy abruptly (rather than tapering) experience recurrence of vasomotor symptoms within weeks, regardless of how long they were on therapy. Gradual tapering is recommended when discontinuing.

~1–2 million

Americans are estimated to use compounded bioidentical hormones annually, though precise figures are difficult to obtain given the absence of centralized dispensing data for compounded preparations.

40+

warning letters were issued by the FDA to compounding pharmacies making unsubstantiated claims about BHRT products between 2008 and 2020, reflecting ongoing regulatory concerns about marketing claims that exceed available evidence.

Up to 68%

potency variability was documented in a 2012 FDA sampling study of compounded hormone products — meaning actual hormone content can differ substantially from labeled dose. This underscores the importance of using PCAB-accredited pharmacies.